3 completed. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 1 | Completed 1 |
Follow margetuximab: new trials by email Literature Review of margetuximab trials Research Report on margetuximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms tebotelimab 1 mg, tebotelimab 3 mg, tebotelimab 10 mg - Advanced Solid Tumors, Hematologic Neoplasms | Phase 1 | Completed | MacroGenics | 277 | 2017-08-18 | 2023-12-21 |
| Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer Margetuximab 10 mg/kg, Margetuximab 15 mg, Pembrolizumab - Gastric Cancer, Stomach Cancer | Phase 1 / Phase 2 | Completed | MacroGenics | 95 | 2016-01-01 | 2025-03-17 |
| Safety Study of MGAH22 in HER2-positive Carcinomas margetuximab - Breast Cancer, Gastric Cancer | Phase 1 | Completed | MacroGenics | 66 | 2010-07-01 | 2025-02-26 |
Stomach Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Esophageal Neoplasms (1) · Hematologic Neoplasms (1) · Ovarian Neoplasms (1) · Small Cell Lung Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1) · Uterine Cervical Neoplasms (1)
MacroGenics (3)
United States (3) · South Korea (2) · Australia (1) · Bulgaria (1) · Canada (1) · Hong Kong (1) · Poland (1) · Singapore (1) · Spain (1) · Taiwan (1) · Thailand (1) · Ukraine (1)
Ashley Ward, MD (1)